Meeting Abstract RDF
pages:- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- more...
- Does Insurance Status Impact Disease-Specific Survival of Appendiceal Neoplasms?
- Does Prior Exposure to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Cause Acute Pancreatitis or Impact Disease Severity? A Systematic Review and Meta-Analysis
- DOES TENOFOVIR GEL - OR DO OTHER VAGINAL MICROBICIDE PRODUCTS - AFFECT DETECTION OF BIOMARKERS OF SEMEN EXPOSURE?
- DOES THE ABSENCE OF PREOPERATIVE CYSTOURETHROSCOPY AFFECT SUCCESS RATES OF MALE SLINGS FOR POST-PROSTATECTOMY INCONTINENCE?
- Does the omission of preoperative cystourethroscopy affect the success rate of postprostectomy incontinence procedures?
- Don't Get Salty, Baby! A Rare Case of Geller Syndrome
- Donor-Derived Cell-Free DNA (dd-cfDNA) Levels in Stable Pediatric Kidney Transplant Recipients
- Donors and Drugs: How Often Do They Mix? Utilization of Donors Based on Toxicology Findings.
- Dose-Dependent Suppression of Ovulation and Ovarian Activity by Elagolix in Healthy Premenopausal Women.
- Double Bridge Approach for Treatment of Acute Mitral Regurgitation from Ruptured Chordae
- DOUBLE BRIDGE APPROACH FOR TREATMENT OF ACUTE MITRAL REGURGITATION FROM RUPTURED CHORDAE
- DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF HEPATOCYTE GROWTH FACTOR GENE THERAPY IN PAINFUL DIABETIC NEUROPATHY
- Doxycycline alters the expression profile of proinflammatory cytokines and chemokines in human endometrial cells.
- Driving Simulator Performance Ninety Minutes Post Propofol Colonoscopy
- DROSPIRENONE 4MG AND ITS INFLUENCE ON DYSMENORRHEA INTENSITY: RESULTS FROM A PHASE III CLINICAL TRIAL
- Drug survival is superior among patients treated with guselkumab compared to adalimumab in the voyage 1 trial
- Dual use of combustible and electronic cigarettes: patterns and associations between products
- Duodenal Adenocarcinoma Masquerading as Gastroenteritis: A Case Report
- Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials
- Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials
- Dupilumab for adolescents with moderate-to-severe atopic dermatitis: Results from a phase 3, randomized, double-blinded trial
- Dupilumab for adolescents with moderate-to-severe atopic dermatitis: Results from a phase 3, randomized, double-blinded trial
- Dupilumab for Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded Trial
- Dupilumab Improves Asthma Control as Assessed by Total and Individual Item Scores of the 6-Item Asthma Control Questionnaire in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Studies
- Dupilumab Improves Sinus Opacification in All Sinuses in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Results From the SINUS-24 Phase 3 Study
- Dupilumab Improves Upper and Lower Airway Outcome Measures in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Studies
- Dupilumab rapidly improves sense of smell in patients with severe chronic rhinosinusitis with nasal polyps: Pooled results from the SINUS-24 and SINUS-52 phase 3 studies
- Dupilumab reduces need for systemic corticosteroid use, sinonasal surgery in patients with severe chronic rhinosinusitis with nasal polyps: Pooled results from the SINUS-24, SINUS-52 phase 3 studies
- Dupilumab Treatment Improves Sense of Smell in Patients With Chronic Rhinosinusitis With Nasal Polyps - Pooled Results From the SINUS-24 and SINUS-52 Phase 3 Trials
- Dupilumab with topical corticosteroids results in rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across all anatomic regions over 52 weeks